Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Cardio Diagnostics (NASDAQ: CDIO) Unveils Innovative Blood Test to Detect Early Stages of Coronary Heart Disease

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is engaged as an artificial intelligence-driven precision cardiovascular medicine company, which is focused on developing products and treatments for cardiovascular disease (CVD) prevention and early detection. Shares of the CVD diagnostics company are skyrocketing 146% through early trading on Tuesday, February 28, 2023. Over the past three months, Cardio Diagnostics has seen average daily volume of 512,790 shares. However, volume of 55.35 million shares or dollar volume of around $171.03 million, has already exchanged hands through early trading.

Shares of Cardio Diagnostics are soaring after the company announced the launch of PrecisionCHD, an integrated epigenetic-genetic blood test that can detect early stages of coronary heart disease (CHD). PrecisionCHD represents the second clinical test that has been developed using the company proprietary AI-focused Integrated Epigenetic-Genetic Engine. The initial test product, Epi+Gen CHD, is a three-year CHD risk assessment test, which was launched in 2021.

The PrecisionCHD product uses epigenetic and genetic biomarkers along-side a machine-learning model developed using billions of genomic and epigenomic data points. As a result, the PrecisionCHD test is able to detect CHD with sensitivity greater than 75% for both men and women. The key to the strong sensitivity in the test is derived from a provider-only Actionable Clinical Intelligence platform, which maps out a patient’s unique biomarker profile and factors in modifiable risk factors like diabetes, hypertension and other factors that can increase the risk for CHD.

“While we are incredibly proud of the work we’ve done to bring PrecisionCHD to the market and the impact this test can have in improving the lives of millions around the world, we understand how timely it was that we were building in an era of Artificial Intelligence, high-performance computing, and high-throughput epigenetics,” said Meesha Dogan, Ph.D., the CEO and Co-Founder of Cardio Diagnostics. “PrecisionCHD would not have been possible without Cardio Diagnostics being at the forefront of pioneering technology at the intersection of epigenetics, genetics, and Artificial Intelligence focused on reducing the burden of the number one killer. PrecisionCHD and Epi+Gen CHD are tools to get ahead of coronary heart disease for healthcare providers, employers, and payers in this era because this is the age of AI-enabled precision medicine.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Cardio Diagnostics (NASDAQ: CDIO) Unveils Innovative Blood Test to Detect Early Stages of Coronary Heart Disease appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.